Neuroendocrine tumors in Panama: A nationwide database analysis

Cukier, Moisés; Vergara, Ruth; Mendez-Rios, Jorge D.; Castillo, O.; Barrera, Irma; Tello, Eliecer; Achtar, Olivia El; Loo, Yong; Tapia, Héctor; Pérez, Guadalupe; Peña, M.

doi:10.3892/mco.2021.2319

Cited by 3 publications

(2 citation statements)

References 26 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The liver is the most common site of NET metastasis. Due to improved diagnostic tools and an increase in early diagnosis, the majority of cases at the time of diagnosis are graded as G1; most of these are non-metastatic, but only by a small margin [56].…”

Section: Neuroendocrine Tumoursmentioning

confidence: 99%

Role of Somatostatin Signalling in Neuroendocrine Tumours

Rogoza

Megnis

Kudrjavceva

et al. 2022

IJMS

View full text Add to dashboard Cite

Somatostatin (SST) is a small peptide that exerts inhibitory effects on a wide range of neuroendocrine cells. Due to the fact that somatostatin regulates cell growth and hormone secretion, somatostatin receptors (SSTRs) have become valuable targets for the treatment of different types of neuroendocrine tumours (NETs). NETs are a heterogeneous group of tumours that can develop in various parts of the body, including the digestive system, lungs, and pituitary. NETs are usually slow growing, but they are often diagnosed in advanced stages and can display aggressive behaviour. The mortality rate of NETs is not outstandingly increased compared to other malignant tumours, even in the metastatic setting. One of the intrinsic properties of NETs is the expression of SSTRs that serve as drug targets for SST analogues (SSAs), which can delay tumour progression and downregulate hormone overproduction. Additionally, in many NETs, it has been demonstrated that the SSTR expression level provides a prognostic value in predicting a therapeutic response. Furthermore, higher a SSTR expression correlates with a better survival rate in NET patients. In recent studies, other epigenetic regulators affecting SST signalling or SSA–mTOR inhibitor combination therapy in NETs have been considered as novel strategies for tumour control. In conclusion, SST signalling is a relevant regulator of NET functionality. Alongside classical SSA treatment regimens, future advanced therapies and treatment modalities are expected to improve the disease outcomes and overall health of NET patients.

show abstract

Section: Neuroendocrine Tumoursmentioning

confidence: 99%

Role of Somatostatin Signalling in Neuroendocrine Tumours

Rogoza

Megnis

Kudrjavceva

et al. 2022

IJMS

View full text Add to dashboard Cite

show abstract

“…The NET primary tumor sites were found in the gastroenteropancreatic system and the small bowel [ 20 ]. Recently, two cohorts were evaluated in Panamá between 2016 and 2019, with NET occurrence at a mean age of 60 years, with a diagnosis grade of G1, and with the liver as the organ most affected [ 21 ]. Finally, a Brazilian registry of 1000 patients was evaluated over 33.7 months; the survival rate in the study was 29.3%, and the prevalence was 71.6% for thoracic NETs and 20.2% for gastroenteropancreatic tumors [ 18 ].…”

Section: Introductionmentioning

confidence: 99%

Neuroendocrine Tumors: An Analysis of Prevalence, Incidence, and Survival in a Hospital-Based Study in Ecuador

Escobar

Villardón

Gonzalez³

et al. 2022

Healthcare

View full text Add to dashboard Cite

Neuroendocrine tumors (NETs) represent a heterogeneous malignancy group of neoplasms, with a limited amount of data from Latin America. Thus, this observational study aimed to provide data about the prevalence, incidence, and survival rates for NET in Ecuadorian hospitals. The study was conducted using data from the Society for the Fight Against Cancer (SOLCA). We evaluated patients with NETs (2000–2020) using the HJ-Biplot method and Cox proportional hazards. Annual age-adjusted incidence and limited-duration prevalence in multivariable analyses as well as hazard ratios (HRs) for mortality and survival were obtained. In the years 2000–2020, the age-adjusted incidence rate increased by 9-fold in the stomach and by 7-fold in the breast. The incidence rates were 1.38 per 100,000 persons in the lung and at 1.79 per 100,000 persons in gastroenteropancreatic sites (rectum, stomach, and pancreas). The prevalence increased from 0.0027% in 2000 to 0.0736% in 2019 and 0.0245% in 2020. Overall survival was worse for metastatic NETs (HR, 4.061; 95% CI, 1.932–8.540; p < 0.001) and advanced local NETs (HR, 2.348; 95% CI, 1.007–5.475 p < 0.048) than for localized NETs. In conclusion, the NET incidence increased in the last 20 years and survival decreased over time, especially for metastatic tumors in the pancreas and the nostril.

show abstract

Impact of sex differences on patients with neuroendocrine neoplasms during hospital admission

Tan,

Cramer,

Vijayvergia

et al. 2024

Ther Adv Med Oncol

View full text Add to dashboard Cite

Background: Sex disparities are known modifiers of health and disease. In neuroendocrine neoplasms (NENs), sex-based differences have been observed in the epidemiology and treatment-related side effects. Objectives: To examine sex differences in demographics, diagnoses present during hospital admission, comorbidities, and outcomes of hospital course among hospitalized patients with NENs. Design: Retrospective analysis. Methods: A descriptive analysis of sex differences was performed on patients with NENs discharged from U.S. community hospitals in 2019 from the National Inpatient Sample (NIS), Healthcare Cost and Utilization Project, and Agency for Healthcare Research and Quality. Results: A total of 7334 patients with NENs were identified; 4284 patients had primary NENs, and 3050 patients had metastatic NENs. In total, 48.7% were males and 51.3% were females. Distributions of race and ethnicity, and payer types differed by sex ( p < 0.001 and p = 0.027, respectively). For race and ethnicity, there were more females in White, Black, and Native American races, and Hispanic ethnicity. For payer types, female predominance was seen with Medicare, Medicaid, private insurance, and self-pay groups. Sex differences were seen in diagnosis made during hospital stay. In all NENs, oral ( p = 0.036) and neurologic ( p < 0.001) diagnoses were more common in females; ascites ( p = 0.002), dysphagia ( p = 0.002), biliary ductal obstruction ( p = 0.014), and jaundice ( p = 0.048) were more common in males. In primary NENs, ascites ( p < 0.001) was male predominant. In metastatic NENs, dysphagia ( p = 0.003) and jaundice ( p = 0.034) were male predominant, whereas females had more headaches ( p < 0.001). Nausea and vomiting were female predominant in all NENs ( p < 0.001), primary ( p = 0.044), and metastatic ( p < 0.001) NENs. For comorbidities, arthropathies ( p < 0.001), depression ( p < 0.001), hypothyroidism ( p < 0.001), other thyroid disorders ( p < 0.001), chronic pulmonary disease ( p = 0.002), and obesity ( p < 0.001) were female predominant. Conclusion: There were sex differences in the race and ethnicity, payer types, diagnoses present during hospital admission, and comorbidities among the 2019 NIS hospital discharge sample of patients with NENs.

show abstract

Neuroendocrine tumors in Panama: A nationwide database analysis

Cited by 3 publications

References 26 publications

Role of Somatostatin Signalling in Neuroendocrine Tumours

Role of Somatostatin Signalling in Neuroendocrine Tumours

Neuroendocrine Tumors: An Analysis of Prevalence, Incidence, and Survival in a Hospital-Based Study in Ecuador

Impact of sex differences on patients with neuroendocrine neoplasms during hospital admission

Contact Info

Product

Resources

About